• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Stevanato Group S.p.A. (Amendment)

    2/14/24 10:43:27 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care
    Get the next $STVN alert in real time by email
    SC 13G/A 1 d759440dsc13ga.htm SC 13G/A SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Amendment #3

    Under the Securities and Exchange Act of 1934

     

     

    Stevanato Group S.p.A.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    T9224W109

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    This Schedule is filed pursuant to Rule 13d-1(b)

    The information required in the remainder of this cover page (except any items to which the form provides a cross-reference) shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

     

     

     


    CUSIP NO. T9224W109

     

     1)   

     Name of Reporting Person

     Ameriprise Financial, Inc.

     

     S.S. or I.R.S. Identification No. of Above Person

     IRS No. 13-3180631

     2)  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☒*

     

    *   This filing describes the reporting person’s relationship with other persons, but the reporting person does not affirm the existence of a group.

     3)  

     SEC Use Only

     

     4)  

     Citizenship or Place of Organization

     

     Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5)   

     Sole Voting Power

     

     0

       6)  

     Shared Voting Power

     

     1,097,823

       7)  

     Sole Dispositive Power

     

     0

       8)  

     Shared Dispositive Power

     

     1,098,308

     9)   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     1,098,308

    10)  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11)  

     Percent of Class Represented by Amount In Row (9)

     

     3.22%

    12)  

     Type of Reporting Person

     

     HC


    CUSIP NO. T9224W109

     

     1)   

     Name of Reporting Person

     

     TAM UK International Holdings Limited

     2)  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☒*

     

    *   This filing describes the reporting person’s relationship with other persons, but the reporting person does not affirm the existence of a group.

     3)  

     SEC Use Only

     

     4)  

     Citizenship or Place of Organization

     

     England and Wales

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5)   

     Sole Voting Power

     

     0

       6)  

     Shared Voting Power

     

     0

       7)  

     Sole Dispositive Power

     

     0

       8)  

     Shared Dispositive Power

     

     0

     9)   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     0

    10)  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11)  

     Percent of Class Represented by Amount In Row (9)

     

     0%

    12)  

     Type of Reporting Person

     

     FI


    CUSIP NO. T9224W109

     

     1)   

     Name of Reporting Person

     

     Threadneedle Holdings Limited

     2)  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☒*

     

    *   This filing describes the reporting person’s relationship with other persons, but the reporting person does not affirm the existence of a group.

     3)  

     SEC Use Only

     

     4)  

     Citizenship or Place of Organization

     

     England and Wales

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5)   

     Sole Voting Power

     

     0

       6)  

     Shared Voting Power

     

     0

       7)  

     Sole Dispositive Power

     

     0

       8)  

     Shared Dispositive Power

     

     0

     9)   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     0

    10)  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11)  

     Percent of Class Represented by Amount In Row (9)

     

     0%

    12)  

     Type of Reporting Person

     

     FI


    CUSIP NO. T9224W109

     

     1)   

     Name of Reporting Person

     

     TAM UK Holdings Limited

     2)  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☒*

     

    *   This filing describes the reporting person’s relationship with other persons, but the reporting person does not affirm the existence of a group.

     3)  

     SEC Use Only

     

     4)  

     Citizenship or Place of Organization

     

     England and Wales

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5)   

     Sole Voting Power

     

     0

       6)  

     Shared Voting Power

     

     0

       7)  

     Sole Dispositive Power

     

     0

       8)  

     Shared Dispositive Power

     

     0

     9)   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     0

    10)  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11)  

     Percent of Class Represented by Amount In Row (9)

     

     0%

    12)  

     Type of Reporting Person

     

     FI


    CUSIP NO. T9224W109

     

     1)   

     Name of Reporting Person

     

     Threadneedle Asset Management Holdings Limited

     2)  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☒*

     

    *   This filing describes the reporting person’s relationship with other persons, but the reporting person does not affirm the existence of a group.

     3)  

     SEC Use Only

     

     4)  

     Citizenship or Place of Organization

     

     England and Wales

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5)   

     Sole Voting Power

     

     0

       6)  

     Shared Voting Power

     

     0

       7)  

     Sole Dispositive Power

     

     0

       8)  

     Shared Dispositive Power

     

     0

     9)   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     0

    10)  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11)  

     Percent of Class Represented by Amount In Row (9)

     

     0%

    12)  

     Type of Reporting Person

     

     FI


    CUSIP NO. T9224W109

     

     1)   

     Name of Reporting Person

     

     TC Financing Ltd

     2)  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☒*

     

    *   This filing describes the reporting person’s relationship with other persons, but the reporting person does not affirm the existence of a group.

     3)  

     SEC Use Only

     

     4)  

     Citizenship or Place of Organization

     

     England and Wales

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5)   

     Sole Voting Power

     

     0

       6)  

     Shared Voting Power

     

     0

       7)  

     Sole Dispositive Power

     

     0

       8)  

     Shared Dispositive Power

     

     0

     9)   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     0

    10)  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11)  

     Percent of Class Represented by Amount In Row (9)

     

     0%

    12)  

     Type of Reporting Person

     

     FI


    CUSIP NO. T9224W109

     

     1)   

     Name of Reporting Person

     

     Threadneedle Asset Management Limited

     2)  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☒*

     

    *   This filing describes the reporting person’s relationship with other persons, but the reporting person does not affirm the existence of a group.

     3)  

     SEC Use Only

     

     4)  

     Citizenship or Place of Organization

     

     England and Wales

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5)   

     Sole Voting Power

     

     0

       6)  

     Shared Voting Power

     

     0

       7)  

     Sole Dispositive Power

     

     0

       8)  

     Shared Dispositive Power

     

     0

     9)   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     0

    10)  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11)  

     Percent of Class Represented by Amount In Row (9)

     

     0%

    12)  

     Type of Reporting Person

     

     FI


    CUSIP NO. T9224W109

     

     1)   

     Name of Reporting Person

     

     Threadneedle Investment Services Limited

     2)  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☒*

     

    *   This filing describes the reporting person’s relationship with other persons, but the reporting person does not affirm the existence of a group.

     3)  

     SEC Use Only

     

     4)  

     Citizenship or Place of Organization

     

     England and Wales

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5)   

     Sole Voting Power

     

     0

       6)  

     Shared Voting Power

     

     0

       7)  

     Sole Dispositive Power

     

     0

       8)  

     Shared Dispositive Power

     

     0

     9)   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     0

    10)  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11)  

     Percent of Class Represented by Amount In Row (9)

     

     0%

    12)  

     Type of Reporting Person

     

     FI


    1(a)    Name of Issuer:    Stevanato Group S.p.A
    1(b)    Address of Issuer’s Principal    Piombino Dese (PD) Via Molinella, 17
       Executive Offices:    Padua, Italy 35017
    2(a)    Name of Person Filing:    (a) Ameriprise Financial, Inc. (“AFI”)
          (b) TAM UK International Holdings Limited (“TAMUKI”)
          (c) Threadneedle Holdings Limited (“THL”)
          (d) TAM UK Holdings Limited (“TUHL”)
          (e) Threadneedle Asset Management Holdings Limited (“TAMHL”)
          (f) TC Financing Ltd (“TCFL”)
          (g) Threadneedle Asset Management Limited (“TAML”)
          (h) Threadneedle Investment Services Limited (“TISL”)
          Persons (a) through (h) are sometimes referred to herein as the “Ameriprise Entities”.
    2(b)    Address of Principal Business Office:    (a) Ameriprise Financial, Inc.
          145 Ameriprise Financial Center
          Minneapolis, MN 55474
          (b) Cannon Place, 78 Cannon Street, London, EC4N 6AG
          (c) Cannon Place, 78 Cannon Street, London, EC4N 6AG
          (d) Cannon Place, 78 Cannon Street, London, EC4N 6AG
          (e) Cannon Place, 78 Cannon Street, London, EC4N 6AG
          (f) Cannon Place, 78 Cannon Street, London, EC4N 6AG
          (g) Cannon Place, 78 Cannon Street, London, EC4N 6AG
          (h) Cannon Place, 78 Cannon Street, London, EC4N 6AG
    2(c)    Citizenship:    (a) Delaware
          (b) England and Wales
          (c) England and Wales
          (d) England and Wales
          (e) England and Wales
          (f) England and Wales
          (g) England and Wales
          (h) England and Wales


    2(d)    Title of Class of Securities:    Common Stock
    2(e)    Cusip Number:    T9224W109

     

    3

    Information if statement is filed pursuant to Rules 13d-1(b) or 13d-2(b):

    (a) Ameriprise Financial, Inc.

    A parent holding company in accordance with Rule 13d-1(b)(1)(ii)(G). (Note: See Item 7)

    (b) TAM UK International Holdings Limited

    A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J).

    (c) Threadneedle Holdings Limited

    A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J).

    (d) TAM UK Holdings Limited

    A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J).

    (e) Threadneedle Asset Management Holdings Limited

    A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J).

    (f) TC Financing Ltd

    A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J).

    (g) Threadneedle Asset Management Limited

    A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J).

    (h) Threadneedle Investment Services Limited

    A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J).


    4

    Incorporated by reference to Items (5)-(9) and (11) of the cover page pertaining to each reporting person.

    AFI, as the parent company of the other Ameriprise Entities, may be deemed to beneficially own the shares reported herein by those reporting persons. Accordingly, the shares reported herein by AFI include those shares separately reported herein by those reporting persons.

    Each of the Ameriprise Entities disclaims beneficial ownership of any shares reported on this Schedule.

     

    5

    Ownership of 5% or Less of a Class:

    If this statement is being filed to report the fact as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X).

     

    6

    Ownership of more than 5% on Behalf of Another Person: Not Applicable

     

    7

    Identification and Classification of the Subsidiaries Which Acquired the Security Being Reported on by the Parent Holding Company:

    AFI: See Exhibit I

     

    8

    Identification and Classification of Members of the Group:

    Not Applicable

     

    9

    Notice of Dissolution of Group:

    Not Applicable


    10

    Certification:

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect.


    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 14,2024

     

    Ameriprise Financial, Inc.
      By: /s/ Michael G. Clarke
      Name: Michael G. Clarke
      Title: Senior Vice President, North America Head of Operations & Investor Services
    TAM UK International Holdings Limited
    Threadneedle Holdings Limited
    TAM UK Holdings Limited
    Threadneedle Asset Management Holdings Limited
    TC Financing Ltd
    Threadneedle Asset Management Limited
    Threadneedle Investment Services Limited
    By   Columbia Management Investment
      Advisers, LLC, as Attorney in Fact
      By: /s/ Michael G. Clarke
      Name: Michael G. Clarke
      Title: Senior Vice President, North America Head of Operations & Investor Services
    Contact Information
    Dominic Geddes
    Global Head of Reporting
    Global Operations and Investor Services
    Telephone: +442074645779


    Exhibit Index

     

    Exhibit I    Identification and Classification of the Subsidiaries which Acquired the Security Being Reported on by the Parent Holding Company.
    Exhibit II    Joint Filing Agreement
    Exhibit III    Powers of Attorney

     

    Get the next $STVN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STVN

    DatePrice TargetRatingAnalyst
    12/2/2025$24.00Equal-Weight
    Morgan Stanley
    12/13/2024$28.00Outperform
    Wolfe Research
    12/3/2024$23.00Equal-Weight
    Morgan Stanley
    4/22/2024Outperform
    Exane BNP Paribas
    11/1/2023$39.00 → $29.00Buy → Hold
    Jefferies
    9/26/2023$33.00Overweight
    Stephens
    9/19/2023Market Outperform
    CJS Securities
    8/24/2023$34.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $STVN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Stevanato Group Reports Revenue of €303.2 Million for the Third Quarter of 2025

    Company delivers 9% revenue growth, record revenue from high-value solutions, expanded margins, and maintains fiscal year 2025 guidance Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2025. Third Quarter 2025 Highlights (comparisons to prior-year period) Revenue increased 9% (11% on a constant currency basis) to €303.2 million. High-value solutions represented a record 49% of total revenue. Gross profit margin increased 240 basis points to 29.2%. Diluted earnings per share were

    11/6/25 6:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Stevanato Group to Participate in Upcoming Investor Conferences

    Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will participate in two upcoming investor conferences. Monday, November 17, 2025, at 8:40 a.m. ET - The 7th Annual Wolfe Research Healthcare Conference in New York City Wednesday, November 19, 2025, at 11:00 a.m. GMT - The Jefferies Global Healthcare Conference in London A live webcast of each event will be available on the Company's website at www.stevanatogroup.com under the "Investors" section. Replays will remain available for approximately 90 days after each event.

    10/31/25 7:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Stevanato Group to Report Third Quarter 2025 Financial Results on November 6, 2025

    Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2025 on Thursday, November 6, 2025, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, November 6, 2025, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pr

    10/22/25 6:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    $STVN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Stevanato Group S.p.A.

    SCHEDULE 13G/A - Stevanato Group S.p.A. (0001849853) (Subject)

    12/3/25 2:38:08 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Stevanato Group S.p.A.

    6-K - Stevanato Group S.p.A. (0001849853) (Filer)

    11/18/25 4:00:03 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Stevanato Group S.p.A.

    6-K - Stevanato Group S.p.A. (0001849853) (Filer)

    11/6/25 4:10:20 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    $STVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on Stevanato Group S.p.A. with a new price target

    Morgan Stanley resumed coverage of Stevanato Group S.p.A. with a rating of Equal-Weight and set a new price target of $24.00

    12/2/25 8:34:50 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Wolfe Research initiated coverage on Stevanato Group S.p.A. with a new price target

    Wolfe Research initiated coverage of Stevanato Group S.p.A. with a rating of Outperform and set a new price target of $28.00

    12/13/24 8:24:13 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Morgan Stanley resumed coverage on Stevanato Group S.p.A. with a new price target

    Morgan Stanley resumed coverage of Stevanato Group S.p.A. with a rating of Equal-Weight and set a new price target of $23.00

    12/3/24 8:38:45 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    $STVN
    Leadership Updates

    Live Leadership Updates

    View All

    Stevanato Group Announces Results of Annual General Meeting

    -All Resolutions Proposed to Shareholders Passed- Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries today announced that all resolutions proposed to the Shareholders at the Annual General Meeting of Shareholders ("AGM") held virtually on May 22, 2024, have passed. Details of the resolutions submitted to, and approved by, the AGM are included in the explanatory report prepared by the Board of Directors of the Company, which is available on the Company's corporate website at https://ir.stevanatogroup.com/. Shareholders approved, among other things, th

    5/24/24 4:10:00 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Stevanato Group appoints Ugo Gay as Chief Operations Officer

    Strengthening corporate leadership aims to drive operational efficiencies and standardization of global processes. Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life science industries, today announced the appointment of Ugo Gay as its new Chief Operations Officer (COO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240404727049/en/Ugo Gay appointed as Chief Operations Officer of Stevanato Group (Photo: Business Wire) The addition of Ugo Gay underscores Stevanato Group's unwavering commitment to driving opera

    4/4/24 8:00:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Stevanato Group Appoints Riccardo Butta as President, Americas

    The appointment bolsters company's commitment to growth in the region Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the appointment of Riccardo Butta to the role of President, Americas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220202005514/en/Riccardo Butta (Photo: Business Wire) The appointment of a dedicated executive to lead the Company's long-term strategy in the Americas is indicative of the growing regional demand trends and the Company's commitment to broaden its footprint, accelerate i

    2/2/22 8:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    $STVN
    Financials

    Live finance-specific insights

    View All

    Stevanato Group Reports Revenue of €303.2 Million for the Third Quarter of 2025

    Company delivers 9% revenue growth, record revenue from high-value solutions, expanded margins, and maintains fiscal year 2025 guidance Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2025. Third Quarter 2025 Highlights (comparisons to prior-year period) Revenue increased 9% (11% on a constant currency basis) to €303.2 million. High-value solutions represented a record 49% of total revenue. Gross profit margin increased 240 basis points to 29.2%. Diluted earnings per share were

    11/6/25 6:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Stevanato Group to Report Third Quarter 2025 Financial Results on November 6, 2025

    Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2025 on Thursday, November 6, 2025, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, November 6, 2025, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pr

    10/22/25 6:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Stevanato Group Reports Revenue of €280.0 Million for the Second Quarter of 2025

    Company delivers 8% revenue growth, expanded margins, and maintains fiscal year 2025 guidance Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2025. Second Quarter 2025 Highlights (comparisons to prior-year period) Revenue increased 8% to €280.0 million, and high-value solutions represented 42% of total revenue. Gross profit margin increased 210 basis points to 28.1%. Diluted earnings per share were €0.11; adjusted diluted earnings per share were €0.11. Adjusted EBITDA mar

    8/5/25 6:30:00 AM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    $STVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Stevanato Group S.p.A.

    SC 13G/A - Stevanato Group S.p.A. (0001849853) (Subject)

    11/14/24 4:06:28 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Stevanato Group S.p.A.

    SC 13G/A - Stevanato Group S.p.A. (0001849853) (Subject)

    11/14/24 3:30:56 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Stevanato Group S.p.A.

    SC 13G - Stevanato Group S.p.A. (0001849853) (Subject)

    11/14/24 1:28:35 PM ET
    $STVN
    Medical/Dental Instruments
    Health Care